Fractyl Health Reports Third Quarter 2026 Financial Results and Business Updates
FRACTYL HEALTH, INC. (GUTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fractyl Health Reports Third Quarter 2026 Financial Results and Business Updates REMAIN-1 Pivotal Cohort met its six-month co-primary endpoint with high statistical significance (p=0.0023); Revita ® participants retained approximately 80% of GLP-1-induced weight loss
How this was made
The 30-second read
Why it matters
The data could drive short‑term price appreciation as the market digests the trial success and improved cash guidance.
Market read
First‑time disclosure of pivotal trial data and financial guidance for a micro‑cap biotech, offering a fresh catalyst for traders.
What to watch
Potential regulatory delays for the De Novo filing and competition from emerging GLP‑1 alternatives.
Fractyl reports Q3 2026 net loss of $14.2 million versus $45.6 million a year earlier, helped by a $25.7 million non-cash warrant gain; cash of $31.5 million funds operations into Q2 2027 and the company cuts its workforce by about 45%
The GAAP net loss narrowed sharply, but the filing attributes most of the improvement to a non-cash warrant fair value gain rather than operating performance. Operating expenses fell, yet SG&A rose and total operating loss is shown as $18.6 million. Cash of $31.5 million covers operations only into Q2 2027, stockholders' equity is a deficit of $(13.2) million, and the company is restructuring and discontinuing Rejuva. The clinical readout is positive but the financial position is constrained.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expenses, three months ended Sep 30, 2026GAAP | $12.45M | – | decrease of $5.0 million |
| Selling, general and administrative expenses, three months ended Sep 30, 2026GAAP | $6.20M | – | increase of $1.0 million |
| Total operating expenses, three months ended Sep 30, 2026GAAP | $18.65M | – | reduction of $4.0 million |
| Loss from operations, three months ended Sep 30, 2026GAAP | −$18.65M | – | – |
| Interest income, net, three months ended Sep 30, 2026GAAP | $297K | – | $0.1 million higher |
| Change in fair value of warrant liabilities, three months ended Sep 30, 2026GAAP | $4.50M | – | favorable non-cash change of $25.7 million |
| Net loss, three months ended Sep 30, 2026GAAP | −$14.15M | – | decrease in net loss of $31.5 million |
| Net loss per share, basic and diluted, three months ended Sep 30, 2026GAAP | $(1.07) | – | – |
| Adjusted EBITDA, three months ended Sep 30, 2026non-GAAP | negative $16.0 million | – | decrease in the non-GAAP adjusted loss of $4.8 million |
| Research and development expenses, nine months ended Sep 30, 2026GAAP | $41.86M | – | – |
| Selling, general and administrative expenses, nine months ended Sep 30, 2026GAAP | $16.70M | – | – |
| Total operating expenses, nine months ended Sep 30, 2026GAAP | $58.56M | – | – |
| Loss from operations, nine months ended Sep 30, 2026GAAP | −$58.56M | – | – |
| Interest income, net, nine months ended Sep 30, 2026GAAP | $1.32M | – | – |
| Change in fair value of warrant liabilities, nine months ended Sep 30, 2026GAAP | $29.07M | – | – |
| Net loss, nine months ended Sep 30, 2026GAAP | −$30.47M | – | – |
| Net loss per share, basic and diluted, nine months ended Sep 30, 2026GAAP | $(2.30) | – | – |
| Adjusted EBITDA, nine months ended Sep 30, 2026non-GAAP | −$50.34M | – | – |
Capital returns
- No share repurchases or dividends are reported in the filing.
- A 1-for-12 reverse stock split became effective October 2, 2026; all share and per share figures are retroactively adjusted, per footnote (2) to the statement of operations.
- Weighted-average shares outstanding, basic and diluted, were 13,250,080 for the three months ended September 30, 2026, versus 5,387,747 a year earlier (adjusted for the reverse split as printed).
What drove it
- Company explanation for the R&D decrease: reduced spending on the Revita and Rejuva programs, as well as lower personnel-related expenses.
- Company explanation for the SG&A increase: higher personnel-related expenses and stock compensation expenses, partially offset by decreased professional service fees.
- Company explanation for the net loss decrease: a $4.0 million reduction in operating expenses, a $25.7 million favorable non-cash change in the fair value of warrant liabilities, $1.6 million lower non-cash loss from change in fair value of debt, and $0.1 million higher interest income.
- Company explanation for the Adjusted EBITDA improvement: reduced operating expenses excluding stock compensation expenses.
- REMAIN-1 Pivotal Cohort (308 participants, mITT): Revita participants retained approximately 80% of GLP-1-induced weight loss at six months versus sham, with p=0.0023. The filing states 32% of Revita participants were weight stable or had further weight loss versus 18% for sham (post hoc; nominal p=0.020).
- Post hoc ablation-length analysis: 12 to 18 cm ablation showed 43% less regain than sham (4.7% versus 8.2%, n=107 versus 74); 20 cm or more showed 53% less regain than sham (mean regain of 3.8%, n=47), as reported by the company.
- Reprioritization adopted October 21, 2026: workforce reduction of approximately 45%, expected to be completed in Q4 2026, with estimated charges of approximately $2 million for severance and other employee termination-related costs, the majority in Q4 2026.
- Rejuva: internal development discontinued and strategic alternatives being explored. The company states there can be no assurance a transaction will result, and does not intend to disclose further developments unless appropriate or required.
- Reimbursement: AMA published Category III CPT code 1122T for the Revita procedure, effective January 1, 2027. CMS proposed RAPID; the company expects to learn in early January 2027 whether CMS adopts an on-ramp.
- Board: effective November 2, 2026, the Board increased from nine to ten members and appointed Michael Wartell as a Class III director.
Concerns
- Net loss improvement is attributed by the company mainly to the non-cash warrant fair value change ($25.7 million favorable in Q3); the operating loss was $(18,649) thousand for the quarter.
- Cash of $31.5 million is described as sufficient into Q2 2027, a short runway that is also subject to the minimum liquidity covenant under the credit agreement.
- Total stockholders' equity is a deficit of $(13,216) thousand at September 30, 2026, versus $9,458 thousand at December 31, 2025.
- Total liabilities of $79,141 thousand exceed total assets of $65,925 thousand less equity considerations as presented; notes payable, long-term remain $29,234 thousand.
- The forward-looking statements section lists among risks the company's ability to continue as a going concern; the filing does not state a going-concern conclusion.
- FDA pre-submission feedback is described as advisory and non-binding, with no assurance FDA will accept the De Novo submission or grant marketing authorization; final pathway determinations follow review of the complete safety dataset.
- CMS adoption of the RAPID on-ramp is not assured and is expected to be known only in early January 2027.
- Rejuva strategic alternatives carry no assurance of any transaction.
- SG&A rose $1.0 million year over year, which the company attributes to personnel and stock compensation costs.
What to watch
- Late Q4 2026: planned FDA De Novo submission for Revita in post-GLP-1 weight maintenance.
- Q4 2026: completion of the approximately 45% workforce reduction and recognition of about $2 million in termination-related charges.
- January 1, 2027: Category III CPT code 1122T takes effect; early January 2027: company expects CMS RAPID outcome.
- Q1 2027: anticipated topline 12-month data from the REMAIN-1 Pivotal Cohort, including the second co-primary endpoint (proportion maintaining at least 5% total body weight loss versus a pre-specified performance goal of greater than 50%).
- Late 2027: potential FDA marketing authorization; early 2028: potential U.S. commercial launch.
- End of Q2 2027: target quarterly operating cash spending of approximately $8 million; cash runway guidance into Q2 2027.
- Outcome of the Rejuva strategic alternatives review.
- Compliance with the minimum liquidity covenant under the company's credit agreement.
- Q4 2026 Form 10-K Liquidity and Capital Resources disclosure, referenced by the company in the Form 10-Q for the quarter ended September 30, 2026.
Balance sheet and cash flow
- Cash and cash equivalents: $31,515 thousand at September 30, 2026 (text: approximately $31.5 million), versus $81,540 thousand at December 31, 2025.
- Restricted cash: $4,255 thousand at September 30, 2026 and $4,255 thousand at December 31, 2025.
- Working capital: $16,989 thousand at September 30, 2026, versus $69,247 thousand at December 31, 2025.
- Total assets: $65,925 thousand at September 30, 2026, versus $121,402 thousand at December 31, 2025.
- Notes payable, long-term: $29,234 thousand at September 30, 2026, versus $30,586 thousand at December 31, 2025.
- Total liabilities: $79,141 thousand at September 30, 2026, versus $111,944 thousand at December 31, 2025.
- Total stockholders' equity (deficit): $(13,216) thousand at September 30, 2026, versus $9,458 thousand at December 31, 2025.
- Cash runway: the company believes its cash position will fund operations into the second quarter of 2027, through the planned De Novo submission and anticipated 12-month REMAIN-1 Pivotal Cohort data, subject to compliance with the minimum liquidity covenant under its credit agreement.
- Quarterly operating cash spending is expected to be reduced by approximately 50%, to approximately $8 million, by the end of Q2 2027, per the company's expectation.
- No operating cash flow, free cash flow or cash flow statement is included in the filing.
Analysis
Fractyl's third quarter 2026 release is dominated by the REMAIN-1 Pivotal Cohort readout and the company's decision to narrow its focus to Revita. The filing states that Revita participants retained approximately 80% of GLP-1-induced weight loss at six months versus sham (p=0.0023 in the mITT population of 308), and it presents post hoc ablation-length results and interim safety data. Commercially, the company points to a launch plan targeting the top 100 to 200 of about 1,000 accredited bariatric centers, with 30 to 50 centers in the first year, and to the CPT code 1122T effective January 1, 2027. The filing offers no revenue, so the commercial thesis is entirely forward-looking.
On the financial statements, operating expenses fell year over year. R&D was $12,454 thousand in the quarter versus $17,457 thousand, and total operating expenses were $18,649 thousand versus $22,694 thousand. SG&A moved the other way, $6,195 thousand versus $5,237 thousand, which the company attributes to personnel and stock compensation costs. The GAAP net loss of $(14,150) thousand compares with $(45,603) thousand a year earlier, but the release attributes the largest part of that change to a favorable non-cash warrant fair value movement of $25.7 million, with the $4.0 million operating expense reduction listed as a separate item. Adjusted EBITDA, a non-GAAP measure, was negative $16.0 million versus negative $20.8 million.
For the nine months, net loss was $(30,470) thousand versus $(97,227) thousand, with the warrant fair value line at $29,070 thousand versus $(20,724) thousand. Operating loss for the nine months was $(58,565) thousand versus $(73,532) thousand. These nine-month comparisons show the same pattern as the quarter: the operating loss narrowed, while the reported net result depends heavily on non-operating fair value items. Adjusted EBITDA for the nine months was $(50,337) thousand versus $(67,895) thousand.
The balance sheet is the main constraint. Cash and cash equivalents were $31,515 thousand at September 30, 2026, down from $81,540 thousand at December 31, 2025, and the company states this funds operations into Q2 2027, subject to a minimum liquidity covenant. Total stockholders' equity moved to a deficit of $(13,216) thousand from $9,458 thousand, and total liabilities were $79,141 thousand against total assets of $65,925 thousand. The company targets quarterly operating cash spending of about $8 million by the end of Q2 2027, after a roughly 50% reduction. Against this, the Q4 2026 restructuring carries approximately $2 million of charges, and the company has stopped internal Rejuva development.
The filing provides no numeric revenue, gross margin, operating cash flow or prior-quarter comparisons, and no prior outlook was supplied, so no guidance comparison is made. The key items to follow are the late Q4 2026 De Novo submission, the Q1 2027 12-month pivotal data, the CMS RAPID outcome in early January 2027, and whether the cash runway can be extended beyond Q2 2027.
Management, verbatim
In the most rigorous stress test we could conceive, a single Revita procedure met its six-month co-primary endpoint with high statistical significance,
Harith Rajagopalan, M.D., Ph.D., Co-Founder, President and Chief Executive Officer
We expect the capital we have today to be sufficient to fund our planned De Novo submission and upcoming 12-month pivotal data and.
Harith Rajagopalan, M.D., Ph.D., Co-Founder, President and Chief Executive Officer
Not in the filing
stated, not guessed- No revenue or product sales reported; no revenue, gross margin or cost of sales lines.
- No numerical forward guidance for revenue, operating expenses or tax; cash runway into Q2 2027 and the Q2 2027 quarterly operating cash spending target (approximately $8 million) are stated, but guidance object set to null.
- No prior quarter (Q2 2026) figures printed; prior_quarter and qoq_change fields are null throughout.
- No prior-year figures for loss from operations, interest income and warrant fair value for the nine months were given as changes; yoy_change left null where not printed.
- No prior-year (September 30, 2025) balance sheet figures; balance sheet comparisons are to December 31, 2025 and are listed in balance_sheet_cash_flow.
- No operating cash flow, investing cash flow, financing cash flow or free cash flow figures.
- No consensus estimates, analyst expectations or share-price reaction.
- Adjusted EBITDA prior-year and year-to-date changes are printed in the reconciliation table; the nine-month change was not printed as text and is left null.
- No segment or geographic revenue breakdown (single segment; no revenue).
- No prior outlook supplied, so vs_prior_guidance is empty.
- Exact amounts for the warrant fair value and Rejuva discontinuation charges beyond the $2 million severance estimate are not printed.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Fractyl Health (Nasdaq:GUTS) disclosed Q3 financials, a 45% workforce reduction, and pivotal Revita trial results in an 8‑K filing.
Ticker impact
Fractyl Health filed an 8‑K reporting Q3 2026 results and positive pivotal trial data for its Revita procedure.
likely upward pressure as investors price in the pivotal data and improved cash outlook
First disclosure of statistically significant weight‑loss retention results and a 45% workforce cut that halves cash spend, both new material facts.
Market effects
Strengthens the obesity/weight‑loss device sector with a potential new therapeutic category.
US biotech and med‑tech stocks may see modest gains on the back of the data.
Limited to investors focused on clinical‑stage biotech and weight‑loss technologies.
Counterpoint
Skeptics may question long‑term commercial viability and reimbursement pathways despite trial success.
Key entities
- companyFractyl Health, Inc.
Clinical‑stage metabolic therapeutics company focusing on obesity and type‑2 diabetes.
- productRevita
Endoscopic procedure aimed at post‑GLP‑1 weight maintenance.
